Institutional shares held 409 Million
7.56M calls
7.2M puts
Total value of holdings $108B
$1.99B calls
$1.9B puts
Market Cap $141B
534,931,008 Shares Out.
Institutional ownership 76.4%
# of Institutions 3,125


Latest Institutional Activity in AMGN

Top Purchases

Q3 2024
International Assets Investment Management, LLC Shares Held: 2.52M ($666M)
Q3 2024
Assenagon Asset Management S.A. Shares Held: 1.54M ($406M)
Q3 2024
Janus Henderson Group PLC Shares Held: 5.14M ($1.36B)
Q3 2024
Vanguard Group Inc Shares Held: 52.4M ($13.8B)
Q3 2024
Capital World Investors Shares Held: 467K ($123M)

Top Sells

Q3 2024
Pathway Financial Advisers, LLC Shares Held: 13.8K ($3.65M)
Q3 2024
Bank Of America Corp Shares Held: 4.3M ($1.14B)
Q3 2024
Qube Research & Technologies LTD Shares Held: 247K ($65.3M)
Q3 2024
Beutel, Goodman & CO Ltd. Shares Held: 1.1M ($290M)
Q3 2024
California Public Employees Retirement System Shares Held: 2.22M ($586M)

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.


Insider Transactions at AMGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
260K Shares
From 23 Insiders
Grant, award, or other acquisition 170K shares
Bona fide gift 90K shares
Sell / Disposition
266K Shares
From 13 Insiders
Payment of exercise price or tax liability 71.7K shares
Bona fide gift 192K shares
Open market or private sale 2.12K shares

Track Institutional and Insider Activities on AMGN

Follow AMGEN INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMGN shares.

Notify only if

Insider Trading

Get notified when an Amgen Inc insider buys or sells AMGN shares.

Notify only if

News

Receive news related to AMGEN INC

Track Activities on AMGN